Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500
Debt
Debt-to-Equity Ratio0.22
Current Ratio2.74
Quick Ratio2.44
Price-To-Earnings
Trailing P/E Ratio89.56
Forward P/E Ratio65.61
P/E Growth2.97
Sales & Book Value
Annual Sales$2.75 billion
Price / Sales19.14
Cash Flow$5.3232 per share
Price / Cash67.30
Book Value$18.83 per share
Price / Book19.03
Profitability
EPS (Most Recent Fiscal Year)$4.00
Net Income$726 million
Net Margins20.88%
Return on Equity26.64%
Return on Assets14.77%
Miscellaneous
Employees6,200
Outstanding Shares147,000,000
Market Cap$52.65 billion
Illumina (NASDAQ:ILMN) Frequently Asked Questions
What is Illumina's stock symbol?
Illumina trades on the NASDAQ under the ticker symbol "ILMN."
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings results on Monday, July, 30th. The life sciences company reported $1.43 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.11 by $0.32. The life sciences company had revenue of $830 million for the quarter, compared to the consensus estimate of $786.88 million. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The business's revenue was up 25.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.82 earnings per share. View Illumina's Earnings History.
When is Illumina's next earnings date?
What guidance has Illumina issued on next quarter's earnings?
Illumina updated its FY18 earnings guidance on Monday, July, 30th. The company provided earnings per share guidance of $5.35-5.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.87. The company issued revenue guidance of $3.19 billion, compared to the consensus revenue estimate of prior $4.75-4.85.
What price target have analysts set for ILMN?
19 brokerages have issued 1 year price objectives for Illumina's stock. Their predictions range from $200.00 to $400.00. On average, they expect Illumina's stock price to reach $316.3125 in the next year. This suggests that the stock has a possible downside of 11.7%. View Analyst Price Targets for Illumina.
What is the consensus analysts' recommendation for Illumina?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and Eyepoint Pharmaceuticals (EYPT).
Who are Illumina's key executives?
Illumina's management team includes the folowing people:
- Mr. Jay T. Flatley, Exec. Chairman (Age 65)
- Mr. Francis A. deSouza, CEO, Pres & Director (Age 47)
- Mr. Sam A. Samad, CFO & Sr. VP (Age 48)
- Mr. Omead Ostadan, Exec. VP of Operations and Products (Age 46)
- Mr. Marc A. Stapley, Exec. VP of Strategy & Corp. Devel. (Age 48)
Who are Illumina's major shareholders?
Illumina's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.25%), Edgewood Management LLC (3.35%), Jennison Associates LLC (2.92%), Winslow Capital Management LLC (0.62%), Fred Alger Management Inc. (0.53%) and Legal & General Group Plc (0.42%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Daniel Bradbury, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Institutional Ownership Trends for Illumina.
Which major investors are selling Illumina stock?
ILMN stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., American Century Companies Inc., Edgewood Management LLC, Keybank National Association OH, Baird Financial Group Inc., Janus Henderson Group PLC, Frontier Capital Management Co. LLC and California Public Employees Retirement System. Company insiders that have sold Illumina company stock in the last year include A Blaine Bowman, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Insider Buying and Selling for Illumina.
Which major investors are buying Illumina stock?
ILMN stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Jennison Associates LLC, Fred Alger Management Inc., Assenagon Asset Management S.A., Canada Pension Plan Investment Board, Kornitzer Capital Management Inc. KS, Ardevora Asset Management LLP and Point72 Asset Management L.P.. View Insider Buying and Selling for Illumina.
How do I buy shares of Illumina?
Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Illumina's stock price today?
One share of ILMN stock can currently be purchased for approximately $358.25.
How big of a company is Illumina?
Illumina has a market capitalization of $52.65 billion and generates $2.75 billion in revenue each year. The life sciences company earns $726 million in net income (profit) each year or $4.00 on an earnings per share basis. Illumina employs 6,200 workers across the globe.
What is Illumina's official website?
How can I contact Illumina?
Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]
MarketBeat Community Rating for Illumina (NASDAQ ILMN)
MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
